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ABSTRACT
Solid lipid nanoparticles (SLNs) are a category of delivery systems applicable to various
bioactive compounds in the food industry. Compared to conventional emulsions that have a
fluidic oil phase, the mobility and release of bioactive compounds can be controlled by
encapsulation in the solid lipid matrix with appropriate properties. Common approaches of
preparing SLNs are high energy methods and solvent evaporation methods, which have can lead
to degradation of compounds during processing and residues of organic solvent, respectively. In
this thesis, a low energy approach based on the phase inversion temperature method has been
used to prepare SLNs based on anhydrous milk fat (AMF). Food grade surfactant Tween 80 was
used as a surfactant, and beta-carotene was used as a model lipophilic bioactive compound. AMF
and surfactant solution with 0-1.0 M NaCl were mixed to form coarse emulsions that were
heated at 80-95 °C [Celsius degree] for 30 min to induce phase inversion, followed by a fast
cooling process in ice bath. The phase inversion temperature decreased from >95 °C to 73°C
when NaCl increased from 0 to 1.0 M in the aqueous phase. Up to 10% w/w of AMF can be
encapsulated in the system as transparent dispersions, with particle mean diameter smaller than
25 nm. The SLN dispersions were dilution and dialysis stable, and the particle size and turbidity
maintained unchanged during the 90-day storage at room temperature. Compared with betacarotene encapsulated in soybean oil-based nanoemulsion, degradation of beta-carotene in SLNs
was much reduced. The studied SLNs may find unique applications in incorporating lipophilic
bioactive compounds in transparent beverages.

iii

TABLE OF CONTENTS
Chapter I. Introduction and Literature Review ........................................................................ 1
1. Introduction ............................................................................................................................. 2
2. Preparation of SLNs ................................................................................................................ 3
2.1. High energy emulsification methods ................................................................................ 5
2.1.1. High pressure homogenization (HPH) methods ........................................................ 5
2.1.2. Combination of high shear homogenization and ultrasonication methods ................ 6
2.1.3. Supercritical fluid extraction methods ....................................................................... 7
2.2. Low energy emulsification methods................................................................................. 8
2.3. Microemulsion-based SLNs ............................................................................................. 8
3. Factors affect stability of SLNs and their measurements ........................................................ 9
3.1. Particle size ....................................................................................................................... 9
3.2. Surface charge ................................................................................................................ 11
3.3. Crystallization and thermal properties ............................................................................ 11
4. Release and bioavailability of bioactives incorporated in SLNs........................................... 14
5. Conclusions ........................................................................................................................... 18
References ................................................................................................................................. 20
Appendix ................................................................................................................................... 21
Chapter II. Transparent Dispersions of Milk Fat-Based Solid Lipid Nanoparticles for
Delivery of beta-Carotene .......................................................................................................... 45
Abstract ..................................................................................................................................... 46
1. Introduction ........................................................................................................................... 47
2. Materials and Methods .......................................................................................................... 49
2.1. Materials ......................................................................................................................... 49
2.2. Preparation of SLNs dispersions .................................................................................... 49
2.2.1. Preparation of surfactant solutions........................................................................... 49
2.2.2. Preparation of coarse emulsions .............................................................................. 49
2.2.3. Thermal treatment for preparation of SLNs............................................................. 50
2.3. Turbidity measurement ................................................................................................... 50
2.4. Particle size determination.............................................................................................. 50

iv

2.5. Viscosity measurement ................................................................................................... 50
2.6. Differential scanning calorimetry (DSC) ....................................................................... 51
2.7. Atomic force microscopy (AFM) ................................................................................... 51
2.8. X-ray diffraction (XRD) ................................................................................................. 52
2.9. Antioxidant properties .................................................................................................... 52
2.10. Quantification of beta-carotene concentration ............................................................. 52
2.11. Storage stability of SLNs and encapsulated beta-carotene ........................................... 53
2.12. Statistical analysis......................................................................................................... 53
3. Results and Discussion .......................................................................................................... 54
3.1. Influence of salinity and temperature on SLNs formation ............................................. 54
3.2. Influence of surfactant: oil ratio on SLNs formation ..................................................... 54
3.3. Physical properties of AMF studied by DSC ................................................................. 56
3.4. Structure of SLNs studied by AFM and XRD ................................................................ 57
3.4.1 AFM .......................................................................................................................... 57
3.4.2 XRD .......................................................................................................................... 57
3.5. Physical storage stability of SLNs .................................................................................. 58
3.6. Stability of beta-carotene during storage ........................................................................ 60
4. Acknowledgements ............................................................................................................... 62
References ................................................................................................................................. 63
Appendix ................................................................................................................................... 70
Conclusion ................................................................................................................................... 85
Vita ............................................................................................................................................... 86

v

LIST OF TABLES

Table 1.1. Examples of compounds incorporated in SLNs and the surfactants and methods used
in preparation ·······························································································35

vi

LIST OF FIGURES

Figure 1.1. Comparison of a liquid nanoemulsion and solid lipid nanoparticles with respect to the
stabilization of encapsulated lipophilic bioactive compounds ·······································39
Figure 1.2. Common procedures in melt and cold homogenization approaches used to prepare
SLNs ·········································································································40
Figure 1.3. Processes used to prepare SLNs by supercritical extraction of emulsion ············41
Figure 1.4. Comparison of differential scanning calorimetry of bulk triacylglycerides and the
corresponding nanodispersions during cooling at various rates ·····································42
Figure 1.5. Correlations between hexagonal, cubic, and orthogonal arranges of triacylglycerides,
x-ray scattering patterns, and α, β′, and β-crystal polymorphisms ··································43
Figure 1.6. Three models showing the distribution of active compounds in SLNs: Homogeneous
matrix, drug-enriched shell, and drug-enriched core ··················································44
Figure 2.1. Absorbance at 600 nm (Abs600) of dispersions containing 1% w/w AMF and aqueous
phase with 15% w/w Tween 80 dissolved in 0-1.0 M NaCl solutions after heating at a
temperature between 80 and 95 C for 30 min and cooling to room temperature. Error bars are
standard deviations from duplicate samples ····························································71
Figure 2.2A. The change of viscosity during cooling from 95 to 35 ℃ for an emulsion. The phase
inversion temperature (PIT) was determined from the local minimum, as depicted. As shown in
inset, cooling results in the conversion of a W/O/W emulsion to an O/W emulsion. The emulsion
contained 1% w/w anhydrous AMF (water fraction fw =0.99) and an aqueous phase composed of
15% w/w Tween 80 dissolved in a 0.8 M NaCl solution ·············································72
Figure 2.2B. Effects of NaCl concentration on the viscosity of emulsions during cooling from 95
to 35 ℃. Emulsions contained 1% w/w AMF and an aqueous phase with 15% w/w Tween 80
dissolved in 0-1.0 M NaCl solutions. Values of the phase inversion temperature (PIT), obtained
as described in Figure 2, were listed in the legend ····················································73
Figure 2.3. Appearance of emulsions before (top) and after (bottom) heating at 90 C for 30 min.
Emulsions before heating were prepared with 1.0-15.0% w/w AMF and an aqueous phase with
30% w/w Tween 80 dissolved in a 0.8 M NaCl solution. AMF concentration increased by 1%
w/w successively for samples ordered from left to right ·············································74
Figure 2.4. Partial phase diagram showing conditions (×100%w/w for each constituent) of
forming microemulsions (red squares), transparent SLNs dispersions (green circles) and turbid or
phase-separated emulsions (blue triangles) at 25 C formed by the phase inversion temperature
method. Coarse emulsions were prepared by mixing 1-15% w/w AMF with an aqueous phase
with 10-40% w/w Tween 80 dissolved in a 0.8 M NaCl solution and were heated at 90 C for 30
min············································································································75

vii

Figure 2.5. Absorbance at 600 nm (Abs600) of emulsions after heating at 90 C for 30 min and
cooling to room temperature. Emulsions were prepared with 1.0-15.0% w/w anhydrous AMF
and an aqueous phase with 10-40% w/w Tween 80 dissolved in a 0.8 M NaCl solution. Error
bars are standard deviations from duplicate samples··················································76
Figure 2.6. Volume-length mean diameter (d4,3) of emulsions after heating at 90 C for 30 min
and cooling to room temperature. Emulsions were prepared with 1.0-15.0% w/w AMF and an
aqueous phase with 10-40% w/w Tween 80 dissolved in a 0.8 M NaCl solution. Samples that
exhibited creaming within 10 min after thermal treatment are not plotted. Error bars are standard
deviations from duplicate samples ·······································································77
Figure 2.7. Atomic force microscopy topographic image with a dimension of 2 × 2 µm (A) and
height distribution of particles along the measurement line (B). Particle size distribution of SLNs
from light scattering is plotted in (C) for comparison. The SLNs were prepared by heating at 90
C for 30 min using an emulsion prepared with 10% w/w AMF in an aqueous phase with 30%
w/w Tween 80 dissolved in a 0.8 M NaCl solution ···················································78
Figure 2.8. XRD patterns of pristine beta-carotene (blue), AMF (red) and beta-carotene-loaded
SLNs (black). SLNs were prepared by heating at 90 C for 30 min using an emulsion prepared
with 10% w/w AMF in an aqueous phase with 30% w/w Tween 80 dissolved in a 0.8 M NaCl
solution·······································································································81
Figure 2.9. Thermograms of AMF during cooling from 75 to -15 ℃ at 2 and 0.5 ℃/min, followed
by heating from -15 to 75 ℃ at 2 ℃/min································································82
Figure 2.10. Changes of (A) volume-length mean diameter (d4,3) and (B) absorbance at 600 nm
(Abs600) of SLNs dispersions, with and without dialysis, during 90-day storage at room
temperature (21 C). SLNs prepared by heating at 90 C for 30 min using an emulsion prepared
with 10% w/w AMF in an aqueous phase with 30% w/w Tween 80 dissolved in a 0.8 M NaCl
solution. Error bars are standard deviations from duplicate samples ·······························83
Figure 2.11. Changes of antioxidant properties of beta-carotene-loaded SLNs dispersions during
storage at room temperature (21 C), in comparison to a control with beta-carotene encapsulated
in vegetable oil-based nanoemulsion. Error bars are standard deviations from duplicate samples
················································································································84
Figure 2.12. Concentration changes, in natural logarithm values, of beta-carotene loaded in SLNs
dispersions, in comparison to a control of beta-carotene encapsulated in vegetable oil-based
nanoemulsion. Error bars are standard deviations from duplicate samples ························85

viii

CHAPTER I

Introduction and Literature Review
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ABSTRACT
SLNs are nanoparticles that contain solid lipid cores. Like nanoemulsions, SLNs have a
lot of advantages, for example, more stable, have better bioavailability, and have a relatively
transparent appearance. Compared to nanoemulsions that have a fluidic oil phase, the mobility
and release of bioactive compounds in SLNs can be controlled by encapsulation in the solid lipid
matrix with appropriate properties. Approaches of preparing SLNs, high energy methods and low
energy methods, and microemulsion based SLNs, have been compared and discussed in this
review. Many factors may affect the stability of SLNs. Parameters used to characterize the
stability of SLNs including particle size, zeta-potential, thermal and crystallization of lipids, and
so on. In this literature review, bioactivity and bioavailability of bioactives incorporated in SLNs
were also discussed. The studied SLNs may find unique applications in incorporating lipophilic
bioactive compounds in transparent beverages.

2

1. Introduction
Various delivery systems have been studied in recent years to incorporate lipophilic
bioactive compounds for improved distribution, increased stability during processing and
storage, and enhanced bioactivity or bioavailability 1. Oil-in-water (O/W) emulsions are
commonly studied because the lipid core can serve as a carrier of lipophilic bioactives.
Nanoemulsions have received extensive attention because, when compared with conventional
emulsions that have a mean diameter in the range from 200 nm to 100 μm, the much smaller
diameters (about 10-200 nm) of nanoemulsions offer several advantages 2. When particles are
sufficiently small, thermal energy becomes more significant than gravitational energy. Therefore
brownian motion is the main underlying force that cause the sedimentation due to density
difference between the dispersed and continuous phases, which extends the shelf-life 3. Unlike
the turbid appearance of conventional emulsions, nanoemulsions are usually translucent or
transparent, due to the much reduced ability of nanoparticles to scatter visible light. As delivery
systems, studies have shown the enhanced stability and bioavailability of bioactive compounds
like beta-carotene, polymethoxyflavones, resveratrol, curcumin, and dibenzoylmethane after
encapsulation in nanoemulsions 4.

However, nanoemulsions have several limitations. For example, they are often stable
only under a particular set of conditions and may be disintegrated upon dilution 5. Like
conventional emulsions, coalescence and Ostwald ripening can result in the destabilization of
nanoemulsions. When used to encapsulate compounds that can be degraded by environmental
factors such as oxygen and light, the liquid state of the lipid core allows the diffusion of
compounds to oil droplet surfaces where many degradation reactions occur, which is more
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problematic for nanoemulsions because the small dimension of nanodroplets reduces the time
scale to diffuse to droplet surface and provides a large surface area for reactions 6.

Solid lipid nanoparticles (SLNs), possessing a solid lipid core, offer unique features
overcoming some limitations but still maintain the advantages of nanoemulsions with a liquid
core. Bioactive compounds in the solid lipid core have limited mobility and therefore lowered
rate of diffusion to the particle surface 7. This can reduce the degradation of bioactive
compounds by reactions such as exchange oxidation and therefore increase the chemical stability
(Figure 1.1.). The protective properties of the incorporated active compounds of SLNs have been
demonstrated for co-Q10 8. Finally, the solid state of lipid core can limit coalescence to improve
physical stability during shelf-life storage. In this chapter, methods of preparing SLNs are
discussed, followed by typical parameters used to characterize SLNs, before advancing to
reviews about incorporation and release properties of bioactive compounds. Factors affecting the
stability of SLNs, including physicochemistry of lipids and surfactants and preparation
condition, are also discussed.

2. Preparation of SLNs
Various methods have been developed to prepare SLNs. Most techniques established to
prepare nanoemulsions, high energy methods and low energy methods, can be used to prepare
SLNs. In addition, SLNs can be manufactured by forming thermodynamically stable water-in-oil
microemulsions at a temperature corresponding to the liquid state of lipids, followed by cooling
to solidify the lipid core 2. The choice of a preparation method depends on the properties of lipids
and surfactants to be used and the applicability to bioactive compounds to be encapsulated.

4

2.1. High energy emulsification methods
The most common methods used to prepare SLNs are high energy methods, similar to
those employed to prepare conventional nanoemulsions 9. Coarse emulsions are initially prepared
and a mechanical device is then used to generate intense forces to disrupt the large oil droplets to
fine ones. The established high-energy devices include high pressure homogenizers,
microfluidizers, and high power sonication systems. With respect to the melting temperature of
lipids, high energy methods can be classified as being either melt (hot) and cold ones.

2.1.1. High pressure homogenization (HPH) method
HPH is a suitable method for preparation of SLNs. This method generates a disrupt force
through a high pressure, and then the very high shear stress and cavitation forces disrupt the
particles to very small size 10. Steps of preparing SLNs using melt and cold homogenization
methods are summarized in Figure 1.2. 9.

In melt, or hot, homogenization, bioactive compounds are dissolved or dispersed in melt
lipid(s) first, and the hot lipid phase is mixed with a hot aqueous surfactant solution and stirred to
form a coarse emulsion. The quality of coarse emulsion can significantly affect the quality of a
final product. The coarse emulsions are then fed to a high pressure homogenizer and processed to
fine nanoemulsions at temperatures above the melting point of lipids. SLNs are finally produced
by cooling the nanoemulsions under controlled conditions 11. The diameter of SLNs processed
using this method is about 80-300 nm, depending on chemistry and concentration of surfactants
and lipid phase, temperature, and the pressure and number of passes during homogenization 12.
The average size of SLNs may be increased by lipids by using higher melting temperatures and
higher lipid concentration 13. In general, the higher the temperature used in HPH, the smaller the
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particles size can be obtained 14. This occurs because high temperatures decrease the viscosity of
the dispersed phase 15.

The hot HPH method is an effective approach to decrease particle size when preparing
SLNs. However, its high temperature and shear stress have been assumed to be the major cause
of free radical formation, which can cause the degradation of incorporated drug 15. When a
bioactive compound is extremely temperature-sensitive, cold homogenization technique may
become a more viable option 12b. To support, there are also studies reporting the activity of
peptides did not change after cold homogenization 16. In this approach, lipids are heated and then
mixed with bioactive compounds, followed by cryo-processing in liquid nitrogen or dry ice. The
frozen mixture is then milled to reduce dimension, followed by its dispersal in a cold surfactant
solution and subsequent HPH treatment to form SLNs 17. Besides reducing the degradation of
encapsulated compounds, cold homogenization has two addition advantages. First, it can prevent
the formation of super-cooled melts that are liquid lipids at temperatures below the
crystallization point. Super-cooled melts formed due to the small particle dimension and the
effect of surfactant(s). This is because lipids are precooled to form solids before HPH. Second,
cryo-processing solidifies the melt rapidly, which results in a homogenous distribution of
bioactive compounds in the lipid phase and avoids the expulsion from the lipid core as observed
in melt homogenization 18. Effects of HPH on the structure of SLNs and encapsulated
compounds are discussed in greater details below.

2.1.2. Combination of high shear homogenization and ultrasonication methods
High shear homogenization and ultrasound methods are other high energy methods that
can be combined to prepare SLNs at a temperature above the melting point of lipids. Both
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methods are well developed and easy to handle. However, metal contamination due to ultrasonication is a potential problem 19. Typically, a coarse emulsion is first prepared with an
ultrasonic instrument, and high speed stirring is used to further reduce particle size 20. It was also
reported that a higher shear rate during homogenization did not significantly change particle size
but decreased the polydispersity index of emulsions 21. In another study, Sliva et al. 22 compared
risperidone SLNs prepared by hot HPH and ultrasound technique. The authors did not observe
significant difference in the dimension and shape of particles prepared by the two methods.
SLNs produced by HPH however demonstrated better physical stability and a higher drugloading capacity.

2.1.3. Supercritical fluid extraction methods
A novel supercritical fluid extraction of emulsions (SFEE) method has also been
developed to produce SLNs to encapsulate drugs 23. This method is based on the principle that
supercritical fluids can extract an organic solvent from a pre-formed lipid dispersion 24. A carrier
lipid and a lipophilic drug are first dissolved in chloroform, which is then mixed with an aqueous
phase with surfactants. The coarse emulsion can be processed to fine oil droplets by HPH. The
fine emulsion is then sprayed into a continuous extraction chamber for extraction by a counterflow supercritical carbon dioxide (Figure 1.3.). SLNs with a narrow size distribution and a mean
diameter below 30 nm were reported, and the residual solvent content in the final dispersion was
consistently low (below 20 ppm). For food applications, the organic solvent may be adopted for
generally-recognized as safe ethanol and others that can be used as processing aides.
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2.2. Low energy emulsification methods
In low-energy approaches, the formation of tiny oil droplets within oil-water-emulsifier
mixture systems is spontaneous when the composition or environmental conditions are altered 2.
In the solvent evaporation method, lipids and the compound to be encapsulated are first
dissolved in an organic solvent such as ethanol and acetone. After formation of a coarse
emulsion, the organic solvent is evaporated, e.g., at a temperature above the melting point of
lipids, to reduce the particle size, followed by cooling to form SLNs 25. The approach has also
been used to prepare W/O/W SLNs 26. A problem of this method is the low concentration of
lipids in preparation, because a limited concentration of lipids can be dissolved in the organic
solvent. The organic solvent residue is another limitation for food applications.

Theoretically, all low energy approaches used to prepare nanoemulsions can be used to
prepare SLNs by adopting a cooling step. For example, the phase inversion temperature method,
which involves a heating step and another cooling process, may be adopted to prepare SLNs.
However, these low energy methods are not well studied for the preparation of SLNs.

2.3. Microemulsion-based SLNs
Besides adopting techniques used to prepare nanoemulsions, SLNs can be developed
from microemulsions. Principally, warm microemulsions are first prepared with a melt lipid
core, followed by dilution into cold water under stirring to solidify the lipid core in order to form
SLNs. The diluted emulsion can be concentrated by ultrafiltration or freeze drying 27.
Microemulsion-based SLNs preparations do not involve high energy to reduce the particle size,
which is adventages to sensitive bioactive compounds. However, a high surfactant concentration
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is required to prepare microemulsions, and the final process of concentrating SLNs may promote
the aggregation of SLNs and thus affect their dimension 28.

3. Factors affect stability of SLNs and their measurements
Stability of SLNs system is affected by many factors, including chemical and thermal
properties of lipid phase, type and amount of surfactant, and preparation and storage conditions,
which will described below. To characterize the effects of these factors, particle size, zeta
potential and other measurements are used. The adequate characterization of these parameters of
SLNs is also significant to control the quality of product.

3.1. Particle size
Particle size affects both the stability and appearance of colloidal systems. Typically,
colloidal systems with small particle size are more stable and have clearer appearance 29. For
example, delivery systems with particle diameters less than 60-80 nm are transparent but become
turbid or opaque at larger particle size 30. Thus, optical clarity can be used to characterize the
stability of systems with small particles 5. Many factors affect the dimension of SLNs. The
choice of lipid(s) is one of the key parameters in controlling the properties and structure of
SLNs. For example, the average size of SLNs can be decreased by lipids with higher melting
temperatures 13a. This is due to the higher viscosity of lipid core during hot homogenization.
Increasing the lipid content also increases particle size and broadens the particle size distribution
13b

.

In emulsion systems, surfactant type and concentration also have a great effect on particle
size and storage stability. Surfactants decrease interfacial tension and provide sufficient repulsive
interaction forces to prevent flocculation and coalescence. For SLNs, especially thosed formed
9

by melt methods, the effect of emulsifier is of the same importance to properties of SLNs as to
nanoemulsions. For tripalmitin SLNs prepared using melt HPH method 31, when stored at a
temperature lower than 20 °C, gelation of SLNs stabilized with modified starch was retarded
compared with those coated with Tween 20. This is due to the formation of a thick polymeric
layer around the lipid particles that inhibited partices from aggregating. But the gelation would
still occur eventually for SLNs coated with modified starch. While when stored at 37 °C, SLNs
coated with Tween 20 showed a longer stability against aggregation and gelation, which may due
to the not fully crystallized lipid core compared with the fully crystallized lipid core of modified
starch coted SLNs.

Other preparation conditions may also affect the physical stability of SLNs. SLNs with
Compritol 888 ATO as lipid carrier were prepared using hot HPH method 32. The energy
introduced to this system (temperature, light) led to particle size growth and gelation, also to an
increase in zeta potential. On the other hand, packing material (siliconized vials of glass quality)
did not show pronounced effect on the stability of SLNs.

Dynamic light scattering (DLS) is the most commonly used method to measure particle
size of colloidal systems. In DLS, the fluctuation of the intensity of the scattered light, due to the
Brownian motion of particles, is measured 33, and the hydrodynamic radius of individual
particles can be determined via the Stokes-Einstein equation 34. The hydrodynamic radius of a
dispersion can be obtained as the average of individual hydrodynamic radii after weighing their
scattered light intensities 35. This method can be used to measure particles with a dimension from
several nanometers to about 3 micrometers 9 but is inappropriate for larger particles.
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However, it should be noted that DLS does not measure particle size directly and the
assumption of “infinite dilution” 33 is difficult to fulfill. Therefore, additional techniques are
recommended to complement DLS studies, for example, scanning electron microscopy (SEM),
transmission electron microscopy (TEM), and atomic force microscopy (AFM). The advanced
microscopy techniques provide not only particle dimensions but also additional information such
as particle morphology.

3.2. Surface charge
Many polymers used to prepare emulsions, for example, proteins and polysaccharides,
are charged. Information of the electrical charge of particles in a delivery system is of great
importance. Particle charge affects interpartilce against aggregation, binding with biological
surfaces, and interactions with other ingredients in a food matrix 29b.

Surface charge properties of SLNs are important to the stability because of their
significance on the long-range electrostatic repulsion between SLNs. Surface charge of a
colloidal system is usually measured for zeta potential. Generally, dispersions with a zetapotential magnitude higher than 30 mV are physically stabilized by electrostatic repulsion alone
36

. A zeta-potential as low as 8-9 mV in combination with a steric stabilization was also reported

to stabilize SLNs in artificial gastrointestinal media 37.

3.3. Crystallization and thermal properties
Lipids used to prepare SLNs include triglycerides (e.g. tristearin), partial glycerides (e.g.
Imwitor), fatty acids (e.g. stearic acid), steroids (e.g. cholesterol), and waxes (e.g. cetyl
palmitate) 38. Thermal properties and crystalline characteristics of bulk lipid and prepared SLNs
are of great importance, because these parameters are strongly correlated with the incorporation
11

and release rates of bioactive compounds 39. The melting point of core lipid also influences the
preparation temperature, the cooling temperature, and cooling rate in the melt HPH method. The
lipid composition may also affect loading parameters 7, 13b.

Crystallization behavior of lipids in SLNs is different from bulk lipids. The solidification
temperature of lipid core in SLNs may be lower than that of the bulk lipids 9. Nanoparticles
prepared from bulk lipids that are solid at room temperature can exist as super-cooled melts at
room and even refrigeration temperatures over several months 40. Thus, some nanoparticles
prepared from lipids that are solid at room temperature may not be considered as SLNs due to
the present of super-cooled melts at room and refrigerator temperature.

The main reason of formation of supercooled melts is the nano-scale size of SLNs. The
presence of nuclei is a prerequisite of crystallization 41, and the formation of a sufficient number
of nuclei is less possible in nanoparticles. Besides the small size of nanoparticles, surfactants
play an additional role in controlling crystallization process because the number of lipid
molecules interacting with the hydrophobic emulsifier tail groups can be large enough to
modulate the crystallization properties. Thus, surfactant chemistry can affect both melting point
and melting enthalpy of lipids 42. Saturated phospholipids can increase the crystallization
temperature, thus promote crystallization of SLNs at a higher temperature during cooling
process42. Egg lecithin was also reported to induce crystallization at higher temperatures than
soybean lecithin 43.

The lipid composition also determines polymorphisms of lipid crystals (Figure 1.4). The
β-form crystals are thermodynamically more stable than the α-form crystals and have the highest
melting point 13b. Lipids tend to transform from α to β polymorphic form during storage. This
12

transformation of the lipid crystal leads to an overall morphological change of the lipid particles
from a spherical to a needle-like shape, which increases the total surface area. During the
transformation, non-polar lipid surfaces are exposed to water, which, if surfactant present is
insufficient, can causes aggregation of lipid particles to reduce the unfavorable contact between
oil and water 44. As described above, this process can cause precipitation or gelation after certain
storage period. To prove this mechanism, additional surfactant was added to the aqueous phase
prior to crystallization of the lipid phase but after the homogenization 45. In this way, droplet size
was maintained because additional surfactant can interact with the newly formed surfaces during
transformation of crystal polymorphisms, and the SLNs dispersions remained fluid-like,
contrasting with the gel formation of the control group.

Chemical properties of surfactant, lipid phase, and preparation conditions all have an
effect on the polymorphic transition behavior of lipids. Mixing tripalmitin with medium chain
triglycerides or short chain lipid (orange oil) can slow the transition process and improve the
stability of SLNs against particle aggregation and gelation 31. The lipid transition would also
related to surfactant type used. SLNs prepared form high melting surfactants (high melting
lecithin and Tween 60) had a higher α crystal fraction than SLNs prepared form low melting
surfactants (low melting lecithin and Tween 80) 46. The polymorphic transitions of triglycerides
can be slowed by the presence of saturated lecithin as emulsifier 43. When preparing SLNs with
hot HPP approaches, cooling and heating conditions are important parameters to control crystal
structure. Figure 1.5 shows the effect of cooling conditions on crystal structure. The α-form
crystals are formed around 43 ℃ while β-crystals are usually formed around 61 ℃ 34. When
cooling speed changes, the crystal type formed can also change. A fast cooling rate favors the
formation of α crystals and helps to maintain the spherical structure of SLNs and thus is
13

preferred for the stability of SLNs. Heating and cooling rates also affect the transition of SLNs
from α to β polymorphic forms, which is related to particle aggregation and gelation. A fast
cooling rate decreases the gelation temperature during cooling, while a fast heating rate increases
the gelation temperature during heating. Fast cooling and heating rates also decrease coalescence
enthalpy, but favor the formation of supercooled melt. Thus, careful selections of cooling and
heating rates are required to form stable SLNs suspensions 47.

Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) are widely used to
investigate the structure of lipids. In DSC, thermal properties are measured based on the fact that
lipid structures formed at various conditions possess different melting points and melting
enthalpies. Conversely, XRD can used to study the existence and type of crystalline structures 48.
These two methods are usually combined to determine the melting point, melting enthalpy,
crystal type, crystal transformation and solid state of lipids in SLNs 49.

4. Release and bioavailability of bioactives incorporated in SLNs
Many SLNs systems have been developed for topical applications, oral administration
and parenteral administration of bioactives, listed in Table 1. SLNs systems developed for food
applications are rare compared with SLNs for pharmaceutical and cosmetic applications.
However, many drugs are loaded in SLNs using food grade lipids and emulsifiers (lecithin,
Tween, and so on) 12c, which can be used to guide studies targeted for food applications. Physical
stability of SLNs and stability, incorporation, release, and bioavailability of drugs loaded in
SLNs are significant parameters to be considered to study these systems.

Three types of SLNs have been developed to incorporate active ingredients: homogenous
matrix model, drug-enriched shell model, and drug-enriched core model (Figure 1.6.) 50. These
14

models are due to the partitioning of drug between lipid phase and aqueous surfactant phase
during particle formation. The homogenous matrix model is thought to be formed when applying
a cold homogenization method or when incorporating very lipophilic drugs, while the other two
models are obtained due to phase separation and fast precipitation of drugs during the cooling
process, respectively 18. When producing SLNs by hot methods, drugs are first loaded in melt
lipids and tend to partition to the aqueous phase. When temperature rises or when surfactant
concentration increases, the solubility of drugs in the aqueous phase increases, resulting in the
increased drug partitioning to the aqueous phase. During cooling, the solubility of drugs in the
aqueous phase decreases and drugs start to repartition to the lipid phase. When temperature
reaches the recrystallization temperature, a solid lipid core starts to form, incorporating drugs
with an amount depending on the solubility of drugs. Upon further cooling, drugs can continue to
partition to the lipid phase but the already-solidified lipid core cannot incorporate anymore
drugs, forming the outer shell rich in drugs. Lastly, SLNs with a drug-enriched core are formed
when the drug precipitates before lipids. This can occur in the case when dissolving a drug in
lipid melts close to its saturation solubility. If drugs supersaturate in the lipid phase during
cooling and crystallize before the lipids recrystallize. Further cooling leads to further
crystallization of drugs until reaching the recrystallization temperature of lipids. In the final
stage, a solid lipid shell forms around the solid core, resulting in SLNs with drug-enriched core
12b

.

The properties of drugs being released from SLNs are a function of SLNs structures.
When drugs are mostly in the shell (Figure 1.6), burst release is commonly observed 19; 51. In
contrast, a prolonged release can also be achieved by forming SLNs with drug-rich cores or a
homogenous structure 11a, 52.
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Particle size (surface area) of SLNs greatly affects the extent of burst release 19, 50.
Reduced burst release was observed with an increase in particle size, and a prolonged release can
be obtained when the particle size is sufficiently large 17. In the drug-enriched shell model
(Figure 1.6.), the drug in the outer shell has a relatively short distance of diffusion, resulting in a
burst release. This was demonstrated for nisin encapsulated in SLNs, showing a high percentage
of release in the first day but a prolonged release through the 25 day period 53. This enabled the
antibacterial activity against Listeria monocytogenes and Lactobacillus plantarum for up to 20
and 15 days, respectively, which was much longer than only the one and three-day activity for
free nisin 53.
During storage, α and β' type crystals can transform to more stable, ordered β type
crystals 13b. The formation of highly crystallized lipid with perfect lattices can lead to drug
expulsion and formation of drug crystals in the aqueous SLNs dispersions, resulting in increased
drug degradation 58. To avoid drug exclusion, increase drug incorporation, and prolong drug
release, lipid cores with multiple components can be adopted to increase the distance between
fatty acid chains of the glycerides and decreases the perfectness of crystals. Hard fat is a mixture
of partial glycerides and liquid fractions. SLNs based on hard fat tend to form the less structured
lipid core that increases drug inclusion and avoids drug expulsion 54. This occurs because the
impurities of lipids can retard the recrystallization process. A mixture of solid and liquid lipids
can lead to more imperfections in the crystal, and thus can increase drug loading 55. Some
researcher also call this kind of delivery systems nanostructured lipid matrices (NLC) 12b, which
are solid but not crystalline. In general, the solubility of drugs in the lipid melt is higher than that
in the final solid lipids. A high concentration of drugs leads to immediate drug expulsion during
cooling process. Thus, a new SLNs type with drug-loaded liquid lipid dispersed in the solid lipid
16

core (O/F/W type) has been developed 12b, 56. An increased drug loading was observed in this
delivery systems because of the high solubility of drug in the liquid lipid. At the same time, the
solid lipid around the liquid core can still protect drugs from degradation, as in other SLNs
systems.

Other factors affecting drug release include drug chemistry, emulsifier type and
concentration, the nature of lipid matrix, and preparation methods 51, 57. SLNs stabilized by highmelting surfactants were observed to protect the encapsulated beta-carotene against chemical
degradation better than those with lower melting temperatures 58. This occured because highmelting surfactants can affect the polymorphic transition behavior of lipids to form more αcrystals that not only improve the chemical stability but also accommodate a higher level of
bioactive compounds 46, 58. The effects of drug chemistry were demonstrated in a study showing
burst release of tetracaine and etomidate but prolonged release of prednisolone when these three
compounds were incorporated in SLNs using the same production method 11a.

The high temperature used in hot HPH method and high surfactant concentration can
increase the burst release, which may be prevented by adopting the cold homogenization method
18

. The burst release can also be reduced by adopting a surfactant that does not dissolve drugs or

possibly excluding surfactant in SLNs preparation. Exceptions have also been observed. For
example, proteins loaded in W/O/W SLNs prepared with the solvent evaporation method showed
the reduced burst release at a higher surfactant concentration 59. This may have been caused by
differences in SLNs structures, W/O/W in this study vs. no aqueous phase in regular SLNs. As
for the lipid matrix, the structure can be engineered by blending medium chain triglycerides
(liquid oils) and long chain ones (solid fat), also known as NLC 60. The controlled release can
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thus be obtained by a built-in trigger mechanism to initiate the transformation from α to β form
crystals 55a, 56.

The controlled release of drugs from SLNs has been studied in vitro and in vivo. For
rifampicin, isoniazid, and pyrazinamide incorporated in SLNs using an “emulsion solvent
diffusion” method, drug concentrations were maintained in the plasma for 8 days and in the
organs for 10 days following the oral administration to mice. This contrasted with free drugs that
were cleared in 1-2 days 25a. When tested for mice infected by M. tuberculosis H37Rv, delivery of
drugs using SLNs reduced the dosing frequency 25a. A SLNs formulation of compritol for
intravenous injection also showed reduced phagocytic uptake in vitro and in vivo, corresponding
to the prolonged circulation time 61. Small interfering RNA (siRNA) loaded in SLNs also
showed the prolonged release both in vivo and in vitro, and the in vitro cell studies showed that
the released siRNA maintained its activity 62. Idarubicin loaded in SLNs and in the solution form
was administered to rats by the duodenal route or intravenously 63. A prolonged release and
higher bioavailability were observed for idarubicin loaded in SLNs when compared to the
solution control. For the SLNs treatment, the drug and its metabolite were observed in the brain,
which was not observed for the solution treatment. The ability of SLNs passing the blood-brain
barrier was also reported in others studies, which suggests that the prolonged circulation time of
SLNs causes the accumulation in the brain but not in other organs11b, 64. This characteristic, if
carefully controlled, can be used for the targeted delivery of drugs using SLNs.

5. Conclusions
SLNs are a group of delivery systems with potential for application in the food industry.
SLNs can be prepared using many approaches that are used for conventional nanoemulsions,
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with modifications. SLNs can also be prepared from self-assembled microemulsions. The
physical stability of SLNs can be controlled for particle dimension and surface charge, as well as
the structures of lipid core including the composition and type of crystals. When compared to
conventional emulsions, the mobility and release of bioactive compounds can be controlled by
the properties of solid matrix and thus the degradation of bioactive compounds due to exchange
can be reduced. The release properties of the encapsulated compounds, however, are dependent
on the exact structure of SLNs, with burst release commonly observed for the presence of the
encapsulated compound mostly in the outer shell and prolonged release corresponding to
compounds rich in the lipid core or distributed evenly in the lipid matrix. There are several
problems related to the stability and controlled drug release, including lipid crystal
transformation, super-cooled melts, drug expulsion and degradation of incorporated drug during
processing. These problems can usually be overcome by adopting appropriate lipid
compositions, surfactant type and concentration, and preparation conditions.
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Table 1.1. Examples of compounds incorporated in SLNs and the surfactants and methods used
in preparation.

Incorporated

Emulsifier(s)

Lipid(s)

drug
Tetracaine,

Preparation

Reference

Method
Poloxamer 188*

Compritol 888 ATO*

etomidate,

High pressure

15

homogenization

prednisolone
Camptothecin

Soybean

Stearic acid

lecithin,

High pressure

16

homogenization

Poloxamer 188*
Camptothecin

Soybean

Stearic acid

lecithin,

High pressure

67

homogenization

Poloxamer 188*
Doxorubicin

Epikuron 200*

Stearic acid

Microemulsion

82

Retinol

Xanthan gum,

Campritol 888 ATO*,

High pressure

72 39

Miglyol 812*

homogenization

Campritol 888*

High pressure

Retinoic acid

Soy lecithin,
Tween 80*

Idarubicin

Epikuron 200*

, ,

36

homogenization
Steric acid

35

Microemulsion

79

37

Table 1.1. Continued.

Incorporated

Emulsifier(s)

Lipid(s)

drug

Preparation

Reference

Method
73

Retinyl acetate,

Gelatin,

Cetyl alcohol,

Melt dispersion -

progesterone,

Polyvinyl

cholesterol, tristearin,

solvent

sodium

alcohol (PVA)

monostearate

evaporation

Epikuron 200*

Stearic acid,

Microemulsion

83

PVA

Steric acid

Solvent diffusion

34

Bovine serum

Poly (lactic-co-

Hydrogenated castor

Solvent

79

albumin,

glycolic acid)

oil

evaporation

Small

Lecithin, DSPE-

Solvent

interfering RNA

Polyethylene

Tristearin,
DOTAP(1,2-dioleoyl3-trimethylammonium-

(siRNA)

glycol

propane

cromoglycate
Cyclic
undecapeptide
cyclosporin A
(CyA)
rifampicin,
isoniazid, and
pyrazinamide

Lysozyme,
Insulin

36

evaporation

78

Table 1.1. Continued.

Incorporated

Emulsifier(s)

Lipid(s)

drug
Beta-carotene

Preparation

Reference

Method
74

High-melting

Tripalmitin, medium

High pressure

lecithin, low-

chain triglycerides

homogenization

Glycerol monostearate,

Sonication

84

High pressure

68

melting lecithin,
Tween 60*,
Tween 80*
Hesperetin

Tween 80*

stearic acid
Nisin

Poloxamer 188*, Cetylpalmitate,
Softisan 378*, Softisan
sodium
154*, Imwitor 900*

homogenization

deoxycholate
Beta-carotene

Stearic acid

Lecithin, sodium

High shear

taurocholate

homogenization

Retinyl

Compritol 888

Phosphatidylcholine,

Microemulsion

palmitate

ATO*, palmitic

cetearyl alcohol and

based, HPH

acid

cetearyl glucoside,

Compritol 888

Phosphatidylcholine,

Microemulsion

ATO*, palmitic

cetearyl alcohol and

based, HPH

acid

cetearyl glucoside,

37

85

86

87

Table 1.1. Continued.

*Chemical structures of corresponding commercial names.

Poloxamer 188: poly (ethylene glycol)-block-poly (propylene glycol)-block-poly(ethylene
glycol).

Campritol 888 ATO: Cetyl palmitate, glyceryl behenate.
Epikuron 200: soya phosphatidylcholine.
Miglyol 812: caprylic/ capric Triglyceride.
Tween 80: polyoxyethylene (20) sorbitan monooleate.
Tween 60: polyoxyethylene (20) sorbitan monostearate.
Softisan 378: a blend of triglycerides based on saturated even-numbered, unbranched natural
fatty acids of vegetable origin with a chain length of C8 – C18.
Softisan 154: a blend of triglycerides based on saturated even-numbered, unbranched natural
fatty acids of vegetable origin with a chain length of C14 – C18.
Imwitor 900: glycerylmonostearate, 40-55 %.

38

Figure 1.1. Comparison of a liquid nanoemulsion (left) and solid lipid nanoparticles (right) with
respect to the stabilization of encapsulated lipophilic bioactive compounds. Redrawn based on 7.
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Figure 1.2. Common procedures in melt and cold homogenization approaches used to prepare
SLNs. Adapted from Mehert et al. (2001).
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Figure 1.3. Processes used to prepare SLNs by supercritical extraction of emulsion. Adapted
from Chattopadhyay, et al., (2007).
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Figure 1.4. Comparison of differential scanning calorimetry patterns of bulk triglycerides and
the corresonding nanodispersion during cooling at various rates. Green, red and blue curves
represented cooling at 0.2 °C/min, 2.0 °C/min, and 20 °C/min respectively. The figure is adapted
from Westesen, Bunjes, & Koch, (1997).
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Figure 1.5. Correlations between hexagonal, cubic, and orthogonal arranges of triaglycerides, xray scattering patterns, and α, β′, and β-crystal polymorphisms. Adapted from Westesen, Bunjes,
& Koch, (1997).
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Figure 1.6. Three models showing the distribution of active compounds in SLNs: Homogeneous
matrix (left), drug-enriched shell (middle), and drug-enriched core (right). Redrawn based on 12b.
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CHAPTER II
Transparent Dispersions of Milk Fat-Based Solid Lipid Nanoparticles for Delivery of BetaCarotene

This chapter is a lightly revised version of a paper by the same title submitted to the Journal of
Agricultural and Food Chemistry by Linhan Zhang, Douglas G. Hayes, Guoxun Chen and Qixin
Zhong. The use of “our” in this chapter refers to my co-authors and I. My primary contributions
to this paper include (1) the preparation of sample, (2) the data collection and analysis, (3) the
gathersing and interpretation of literature, and (4) the writing.
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Abstract
Solid lipid nanoparticles (SLNs) are possible vehicles to incorporate lipophilic bioactive
compounds in transparent functional beverages. In this work, AMF and Tween 80 were used to
prepare SLNs by using a phase inversion temperature method, and beta-carotene was used as a
model lipophilic bioactive compound. The phase inversion temperature decreased from >95 C
to 73 C, when NaCl was increased from 0 to 1.0 M in the aqueous phase. At 0.8 M NaCl and
phase inversion by heating at 90 C for 30 min, transparent SLNs dispersions were observed at
AMF level higher than 10% w/w, corresponding to particles smaller than ~25 nm. The SLNs
dispersions were dilution and dialysis stable and maintained turbidity level and particle size
during 90-day storage at room temperature. The degradation of beta-carotene encapsulated in
SLNs was much reduced when compared with its encapsulation in the soybean oil-based
nanoemulsion.

Keywords: Solid lipid nanoparticles, phase inversion temperature method, anhydrous milk fat,
transparent dispersion, beta-carotene, storage stability
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1. Introduction
There are numerous lipophilic bioactive compounds of significance to food,
pharmaceutical, and other consumer products 1. However, low solubility and poor stability are
two major concerns when incorporating these bioactive compounds in products that possess an
aqueous continuous phase. Thus, a suitable delivery system is needed to physically distribute
them in product matrices with maintained chemical stability during storage, either in the
presence or absence of hydrophilic and lipophilic antioxidant compounds 2.
The lipid core of oil-in-water (O/W) emulsions is commonly used to encapsulate
lipophilic bioactive compounds. Furthermore, nanoemulsions, with droplet diameters smaller
than about 200 nm, have the advantages of good physical stability during storage and a
translucent or even transparent appearance 3-4. Nanoemulsions have also shown the enhanced
bioavailability of encapsulated bioactive compounds like beta-carotene 5. If the oil body of
nanoemulsions can be prepared from lipids present in the solid state at typical application
conditions, so-called solid lipid nanoparticles (SLNs), the degradation of encapsulated bioactive
compounds can be much reduced 6. This is because the solid lipid matrix reduces the mobility of
encapsulated compounds diffusing to the particle surface where most of degradation occurs 6. A
variety of SLN systems have been developed as effective delivery agents 7-9. But much work is
needed to fabricate transparent SLN dispersions using low-cost and scalable processes.
SLNs are usually formed by high energy methods such as high pressure homogenization
above or below the melting temperature of lipids 8, 10-11. High energy methods are effective in
reducing particle size but demand high capital and operating costs. Degradation of sensitive
compounds during processing is another concern. Conversely, low energy methods such as those
involving phase inversions due to changes in temperatures or compositions do not require
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specialized equipment and high mechanical energy 3. In particular, the phase-inversion
temperature (PIT) method has been used to prepare transparent nanoemulsions of lemon oil 12.
Since heating lipids above the melting temperature is needed to dissolve lipophilic compounds
before preparing SLNs, it is logical to form transparent SLN dispersions using the PIT method,
which has not been studied.
The phase behavior of water-oil-surfactant systems as a function of surfactant properties,
temperature, and composition is affectively described by the hydrophilic lipophilic
deviation(HLD, eq 1 for nonionic surfactants) 13.
HLD = α - EON – k ACN + b S + Φ(A) + CT (T - Tref)

(1)

Negative and positive HLD values indicate the possibility of forming O/W and W/O type
emulsions, respectively, while a bicontinuous phase behavior corresponds to a HLD value of 0
14

. For an emulsion with a fixed composition, a fine emulsion with small particle size can be

formed during the process of inversion between W/O and O/W emulsions due to changes in
temperature 15-16. Partial inversion was observed for transformation of turbid coarse O/W
emulsions of lemon oil emulsified by Tween 80 (polyoxyethylene (20) sorbitan monooleate) to
transparent nanoemulsions after heating at 90 C for 30 min 12.
where α is a characteristic parameter of the lipophilic part of the surfactant; EON is the number
of ethylene oxide groups per surfactant molecular, ACN is the number of carbon atoms in the
alkyl tail of molecule (or equivalent); Φ(A) is a function of the alcohol (added as a co-surfactant)
type and concentration; S is the salinity of the aqueous phase in wt% of NaCl or equivalent salt;
T is the temperature (°C); Tref is generally taken at 25 °C; and k, b, and CT are constants
characteristic of the surfactant type and electrolyte 13. The value of temperature coefficient CT is
typically larger for an ethoxylated nonionic surfactant than an ionic one 17.
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The first objective of this work was to study the formation of transparent dispersions of
SLNs using the PIT method. AMF was chosen as the solid lipid because it is a commercially
available dairy ingredient. Variables in SLN formation were studied for thermal treatment
conditions, salinity, and composition. The second objective was to study the prevention of
degradation for beta-carotene, a model lipophilic bioactive compound, when encapsulated in
SLNs.

2. Materials and Methods
2.1. Materials
AMF was kindly donated by Land O'Lakes, Inc. (St. Paul, MN). Polyoxyethylene (20)
sorbitan monooleate (Tween 80), NaCl (purity >99.5%), ethanol, hexane, and deionized water
were purchased from Fisher Scientific (Pittsburgh, PA). Soybean oil was a product of Kroger Co.
(Cincinnati, OH). Beta-carotene (predominantly in the trans form) was purchased from MP
Biomedicals, LLC (Solon, OH). Potassium persulfate, 6-hydroxy-2, 5, 7, 8-tet-ramethychroman2-carboxylic acid (Trolox), and 2, 2’-azinobis (3-ethylbenzothiazoline-6-sulfonic acid)
diammonium salt (ABTS) were products of Sigma-Aldrich Corp. (St. Louis, MO).

2.2. Preparation of SLNs dispersions
2.2.1. Preparation of surfactant solutions
NaCl and Tween 80 were dissolved in deionized water at concentrations of 0-1.00 M and
5-40% w/w respectively. The mixtures were stirred overnight to ensure complete dissolution and
heated to 60 ℃ before use.
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2.2.2. Preparation of coarse emulsions
Preparation of coarse emulsions and SLN nanodispersions was investigated based on a
PIT method detailed previously 12, with some modifications. To form a coarse emulsion, AMF
was heated to 60 ℃ for complete melting, followed by mixing with warm (60 C) aqueous phase
under agitation at 1000 rpm using a magnetic stirring plate. The AMF concentration in coarse
emulsions was 1-15% w/w. For encapsulation studies, beta-carotene was dissolved in warm
AMF at a concentration of 6.25 mM before emulsification. To compare impacts of the structure
of lipid body (solid fat vs. liquid oil) on the stability of encapsulated beta-carotene, a control
nanoemulsion was prepared using soybean oil at conditions comparable to the treatment using
AMF.

2.2.3. Thermal treatment for preparation of SLNs
The coarse emulsions were transferred to 4 mL glass vials that were heated for 30 min in
a water bath maintained at a constant temperature (75, 80, 85, 90, or 95 ℃) without stirring.
After thermal treatment, these samples were first cooled at ambient conditions with hand shaking
till a homogenous appearance, followed by quenching in an ice bath under static conditions.

2.3. Turbidity measurement
Turbidity of samples was measured for absorbance at 600 nm (Abs600) using a UV/vis
spectrophotometer (Unicam, Cambridge, UK). Tween 80 solutions at corresponding
concentrations were used as controls.

2.4. Particle size determination
The particle size of samples was measured by using a DelasTM Nano particle analyzer
(Beckman Coulter, Fullerton, CA). In order to avoid multiple scattering effects, all samples were
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diluted to an appropriate concentration in deionized water prior to analysis. The volume-length
mean diameter was calculated as following:
d4,3 = ∑ni di4/∑ni di3

(2)

where ni and di are the number and diameter of the ith group of particles.

2.5. Viscosity measurement
Rheological properties of dispersions were studied with an AR 2000 rheometer (TA
Instrument, New Castle, DE) using a Searle setup (bob outer diameter = 28 mm and cup inner
diameter = 30 mm). After loading the sample, heating to and equilibrated at 95 ℃ for 2 min, a
temperature sweep with a fixed shear rate of 100 s-1 13 was applied from 95 to 25 ℃ at 3 ℃/min.
A thin layer of soybean oil was applied on the top of sample to minimize water evaporation.

2.6. Differential scanning calorimetry (DSC)
DSC (model Q2000, TA Instruments, New Castle, DE) was used to study melting and
crystallization properties of AMF and SLNs during heating and cooling. The transparent SLN
dispersion prepared with 15% AMF and 45% Tween 80 in 0.8 M NaCl as the aqueous phase was
used to generate detectable endothermic and exothermic peaks. A sample corresponding to 5-8
mg AMF or 15-20 mg SLN dispersion was placed in an aluminum pan and hermetically sealed.
An empty pan was used as a reference. The thermal profile was studied by two cycles, with each
cycle following the steps of holding at -15 C for 5 min, heating from -15 to 90 ℃ at 5 ℃/min
and cooling from 90 to -15 ℃ at 20 ℃/min. Heat flow of the samples was recorded using the
instrument software.
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2.7. Atomic force microscopy (AFM)
The shape and dimension of particles were characterized using a NanoScope IIIA
Multimode AFM (Veeco Instruments Inc., Santa Barbara, CA). The SLN dispersion was first
diluted to 10 ppm of AMF using deionized water. Two µL of the diluted sample was dropped on
a freshly cleaved mica disk and dried under ambient temperature (21 C) overnight. A resonant
frequency of about 71.0 kHz and a scan rate of 1.0 Hz were applied. Images were collected at the
tapping mode and analyzed using the instrument software.

2.8. X-ray diffraction (XRD)
Crystallinity of pristine beta-carotene, AMF and beta-carotene-loaded SLNs was studied
by XRD (Panalyticla, Westborough, MA). SLN dispersions were freeze-dried before being
spread on the glass plate and pressed to make a smooth layer. The diffraction spectrum was
acquired at 2°/min for a 2θ range of 5-55°. The Cu KR radiation (λ = 1.54 Å) was generated at
30 kV and 10 mA.

2.9. Antioxidant properties
The antioxidant properties of the emulsions were estimated using an ABTS method 18-19.
This method measures the relative ability of antioxidant substances to scavenge the ABTS+,
which is referenced to Trolox, an antioxidant standard. To generate ABTS+, 7 mM ABTS and
2.45 mM potassium persulfate were dissolved in ethanol and allowed to stand in the dark at room
temperature overnight. The ABTS+ solution was diluted with ethanol to an absorbance of 0.70
(±0.02) at 734 nm. Two µL of Trolox or emulsion was mixed with 2 mL of the ABTS+ solution,
and the absorbance of the mixture at 734 nm was measured after mixing for 15 min. The
percentage inhibition of absorbance at 734 nm was calculated and plotted as a function of
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concentration of Trolox and emulsion. The antioxidant properties were obtained by referring to a
standard curve established from Trolox and expressed as mM Trolox equivalents per mL.

2.10. Quantification of beta-carotene concentration
Beta-carotene concentration in the emulsion was determined using absorbance 20. Twenty
µL of an emulsion sample was extracted by using a mixture composed of 2 mL ethanol and 3 mL
hexane. After hand shaking for 2 min, the upper organic phase was collected. The remainder
aqueous phase was extracted repeatedly until the top phase became colorless. All hexane extracts
were pooled into a 10 mL flask and added with hexane to a total volume of 10 mL. The
absorbance at 450 nm was measured using a UV-Visible spectrophotometer (Unicam,
Cambridge, UK). The concentrations of beta-carotene in emulsions were obtained by referring to
a standard curve established from standard solutions with different amounts of beta-carotene in
hexane.

2.11. Storage stability of SLNs and encapsulated beta-carotene
Physical stability of SLNs
Selected SLN dispersions without beta-carotene and the corresponding dispersions after
dialysis treatment were stored for 90 days at ambient temperature (21 C). The dialysis of NaClcontaining emulsions was conducted using a membrane with a molecular weight cut-off of 3500
Da (Fisher brand, Pittsburgh, PA) which was immersed in bulk distilled water for 48 h that was
exchanged with fresh water every 6 h. Two mL dispersions were included in 4 mL capped glass
vials, and the Abs600 and particle size in individual vials were measured periodically using the
methods described above.
Chemical stability of beta-carotene
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The stability of beta-carotene in SLNs and comparable nanoemulsions prepared with
soybean oil was characterized for changes of both antioxidant properties and beta-carotene
content during room temperature (21 C) storage for 16 days. Samples in 4 mL sealed clear glass
vials were exposed to LED fluorescent light during storage. Individual vials were sampled every
two days for assays of beta-carotene concentration and antioxidant property as above.
Antioxidant properties of SLNs and soybean oil nanoemulsions without beta-carotene were also
determined and used as controls.

2.12. Statistical analysis
All samples were prepared in duplicate. All measurements were repeated at least twice.
Results from all measurements were reported for means and standard deviations. Significant
differences were analyzed with a least-significant-difference (P < 0.05) mean separation method,
assisted by using Statistical Analysis Software (V9.2, SAS Institute, Cary, NC).

3. Results and Discussion
3.1. Influence of salinity and temperature on SLNs formation
The first group of experiments was used to study temperature and NaCl concentration
that are important parameters of HLD (eq 1). Furthermore, based on our preliminary trials,
emulsions with high surfactant concentrations can form gels at high NaCl concentrations during
thermal treatments, while a low surfactant-to-oil ratio (SOR) typically results in phase
separation. Therefore, this group of samples was prepared with 1% w/w AMF and aqueous phase
with 15% w/w Tween 80 and 0-1.0 M NaCl. After heating at 80-95 C for 30 min and cooling to
room temperature, the Abs600 is shown in Figure 2.1. Emulsions with NaCl concentration lower
54

than 0.4 M had no significant change in Abs600 after heating, while those containing 0.6-1.0 M
NaCl showed significant reduction in Abs600 at a heating temperature of 85-95 C. Figure 2.1
also indicates that a lower NaCl concentration was required to transform turbid emulsions to
transparent ones when heated at 95 C than at 90 C.
Figure 2.1 suggests that temperature and NaCl concentration strongly control phase inversion.
Monitoring viscosity changes of emulsions during cooling is a convenient method to characterize
phase behavior and determine the PIT 21-22. Figure 2.2 shows viscosities of samples during
cooling from 95 to 35 C and the determined PIT. Using the emulsion formed from 0.80 M NaCl
as an example, the sample viscosity was small at high temperatures. When the temperature
decreased to about 77 ℃, the viscosity increased quickly and reached a maximum value at 65 C.
Upon further cooling, viscosity decreased until reaching about 55 ℃, followed by an increase
with a further decrease in temperature. Typically, there are two viscosity maxima during cooling,
corresponding to formation of fine W/O and O/W emulsions, and the temperature corresponding
to the lowest viscosity between the two maxima is treated as the PIT 21. For systems with a large
water fraction (fw) as the case of the present study, the viscosity maximum above the PIT is
usually not observed 13, possibly due to the formation of multiple W/O/W emulsions instead of
W/O ones. The PIT of systems with high water content can be approximated by the temperature
at which the viscosity starts to increase during cooling, e.g., 76 ℃ for the system containing 0.8
M NaCl. As presented in Figure 2.2, emulsions containing a higher NaCl concentration had a
lower PIT. According to eq (1), HLD is larger at a higher NaCl concentration, requiring a lower
temperature (PIT) to reach an HLD value of zero, i.e. phase inversion. The remaining
experiments to form SLNs were conducted at NaCl concentration of 0.8 M and thermal treatment
of 90 C for 30 min.
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3.2. Influence of surfactant: oil ratio on SLNs formation
The impact of composition on SLN formation was studied for emulsions with 1.0-15.0%
w/w AMF in the aqueous phase with 10.0-40.0% w/w Tween 80 and 0.80 M NaCl. Samples with
low oil concentrations were transparent before heating (1, 1-3, and 1-7% w/w AMF for the
treatments with 20, 30, and 40% w/w Tween 80 in the aqueous phase, respectively), because
micelles of Tween 80 are capable of dissolving some lipids, forming O/W microemulsions.
These samples remained transparent and had low Abs600 after thermal treatment. Turbid
emulsions with 2-6, 4-10, and 8-14% w/w AMF in samples with 20, 30, and 40% Tween 80 in
the aqueous phase, respectively, became transparent after thermal treatment, while turbid
emulsions were still observed after heating samples with higher AMF concentrations. Some
samples with high AMF concentrations even underwent phase separation, with creaming
observed after 10 min. These observations are demonstrated visually in Figure 2.3A for
emulsions with 30% w/w Tween 80 in the aqueous phase. Consistent with these observations,
values of Abs600 and d4,3 of samples after cooling to room temperature are shown in Figure 2.4A
and 2.4B, respectively. Generally, transparent samples are evidenced by small Abs600 (<0.1
absorbance units) and d4,3 (< ~ 23 nm) because of the inability of small SLNs in scattering visible
light. All samples with the lowest amount of Tween 80 (10% w/w in the aqueous phase) were
turbid before and after heating. Sub-micrometer sized particles (<400 nm) were observed for
samples with 8-10, 12-15, and 15% w/w AMF in the aqueous phase with 20, 30, and 40% w/w
Tween 80, respectively. The standard deviations of d4,3 and widths of size distributions (the latter
not shown) were large for these treatments, possibly because of the deficiency of surfactants
required for phase inversion at the studied conditions. The high polydispersity may also play a
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role. Conditions enabling formation of SLNs are summarized in Figure 3B for this group of
treatments, in the form of a phase diagram.
Our results generally agreed with those of Rao and McClements 12. In their research,
propylene glycol was used in the aqueous phase to enhance the inversion of transparent
nanoemulsions with lemon oil. In contrast, propylene glycol was not observed to enhance the
formation of transparent SLN dispersions in our preliminary studies. This may be due to the
lower solubility and higher melting temperature of AMF than those of lemon oil.
It is worth noting that the stability of surfactant-based systems upon dilution is an
important attribute. For the systems with lemon oil emulsified with Tween 80 12, samples
containing relatively high surfactant concentrations after thermal treatment exhibited increased
turbidity after dilution. The observations were attributed to the instability of microemulsion
subjected to compositional changes. In the present study, all transparent samples remained stable
upon dilution at room temperature. The differences between the two studies perhaps are related
to the interface of lemon oil/water being more fluidic, while the interface between solid lipid
core and water is more rigid in our study. Droplets composed of solid lipids also are less
susceptible to emulsion instability mechanisms such as coalescence and Ostwald ripening. The
structure and storage stability of SLNs are presented in following sections using emulsions
prepared with 10% w/w AMF and an aqueous phase with 30% w/w Tween 80 in 0.8 M NaCl,
after heating at 90 C for 30 min.

3.3. Structure of SLNs studied by AFM and XRD
3.3.1 AFM
Figure 2.5A displays an AFM image of SLNs in a transparent dispersion. Particles were
discrete and mostly spherical. When compared to particle size distribution (Figure 2.5C), particle
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heights measured by AFM (<5 nm, Figure 2.5B) were much smaller, as reported in other studies
23-25

. The difference may be due to the underlying theory for the two methods. An assumption

used in dynamic light scattering (DLS), “infinite dilution” 26, is hard to fulfill. If interactions
among particles occur, common for emulsion systems, the interaction may contribute toward the
diffusion coefficients obtained from DLS. Thus, the estimation of particle size obtained by the
Stokes-Einstein Equation may be overestimated. Additionally, the dimension occupied by
particles may decrease after drying the SLN dispersion for AFM.

3.3.2 XRD
XRD is a convenient technique not only for characterizing SLNs 27-28 but also for
confirming the encapsulation of lipophilic compounds 29, especially beta-carotene, which is
highly crystalline 30-31. AMF also has crystalline structures below its melting temperature 32.
Because AMF is composed of a mixture of lipids, its crystalline structures are dependent on
temperature and cooling rate 33-34. Figure 2.6 shows the XRD spectra of beta-carotene, AMF, and
beta-carotene-loaded SLNs. Beta-carotene showed several sharp peaks, indicating crystallinity,
while AMF possesses smaller and broader peaks, indicating that AMF has mixed morphology at
room temperature. It has previously been suggested that amorphous morphology is dominant, but
crystalline structure is also present in AMF at room temperature 35. For SLNs loaded with betacarotene, because Tween 80 is a non-crystalline compound at ~20 C36-38, the smooth XRD curve
of the beta-carotene-loaded SLNs and its similarity to the spectrum of AMF suggest that betacarotene was embedded in SLNs 39. Detailed structures of AMF crystals however were not
studied in the present work, as it requires temperature-controlled small angle XRD 40-42.
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3.3.3 DSC
Thermograms of AMF and SLNs during heating and cooling cycles are shown in Figure
2.7. During heating, multiple melting temperatures of AMF were observed at about 8.7, 15.3,
and 24.1 C, with the last peak extending to 36.4 C. During the subsequent cooling process, the
crystal formation started at around 17.6 ℃ and the crystalline process of mostly oil happened
around 5.0 °C. The two cycles of heating-cooling process do not showed any differences,
indicating bulk recrystallization of AMF would not affect its crystal type and melting
temperature. The DSC results of AMF agree with previous studies 43-44. Multiple melting
temperatures suggested in Figure 2.7 are due to the fact that AMF is a mixture of triglycerides
containing more than 400 fatty acids, both saturated and unsaturated, including oleic acid,
palmitic acid, myristic acid, and stearic acid 45. First cycle of heating curves of SLN showed a
strong endothermic peak at 15.3 °C. While the other two melting peak showed in the heating
curved of bulk AMF do not present as obvious as in the heating curve of SLN. In the subsequent
cooling cycle of SLN, initial crystal formation temperature is the same as bulk AMF. But the
main exothermic peak happened around -3.2 °C, much lower than bulk AMF. The differences of
crystallization behavior of lipids in SLN agrees with previous study that the solidification
temperature of lipid core in SLN may be lower than that of bulk lipids46. Lipids may exist as
super-cooled melts in SLN47. The differences between first and second cycle of SLN may due to
particle coalescence or free oil in the SLN48-49. Thus, AMF in SLN dispersion is present as a
mixture of solid state and liquid state at room temperature (21 C) in the present study. The DSC
(Figure 2.7) and XRD (Figure 2.6) results suggest that AMF in SLNs does not have extensive
ordered crystalline structures but is present at the amorphous solid state, corresponding to
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nanostructured lipid carriers that are advantageous in encapsulation when compared to SLNs
with highly ordered crystals. 11

3.4. Physical storage stability of SLNs
Figure 2.8 contains Abs600 and d4,3 values of emulsions, stored at room temperature (21
°C) for 90 days, for SLN dispersions with and without dialysis. The initial d4,3 and Abs600 of the
emulsion with NaCl were 25.5 ± 3.0 nm and 0.13 ± 0.02, respectively. During the storage, there
was no significant changes in the Abs600 and d4, 3 (P > 0.05), which were 25.4 ± 1.3 nm and 0.10
± 0.00, respectively, at the end of the storage. Furthermore, dialysis did not change Abs600 and d4,
3

of samples and their stability during storage. Therefore, the AMF-based SLN dispersions

possess excellent physical stability during storage, which again can be attributed to the
elimination of coalescence and Ostwald ripening due to use of solid phase lipids as the dispersed
phase.

3.5. Stability of beta-carotene during storage
Figure 2.9 shows changes in antioxidant potential and concentration of beta-carotene
loaded in SLNs during 16-day storage at room temperature (21 C). To study the influence of
physical structures of lipid droplets on the stability of loaded bioactive compounds, an emulsion
control was prepared by substituting AMF with soybean oil that has a similar average fatty acid
chain length as AMF. The d4,3 of soybean oil nanoemulsion (29.8 ± 0.0 nm) was comparable
with that of SLNs and was stable after 16 day-storage (30.3 ± 1.0 nm). The net antioxidant
potential of beta-carotene in nanoemulsions was determined by subtracting the measured
potential of the corresponding nanoemulsion without beta-carotene. Both net antioxidant
properties and concentration of beta-carotene gradually decreased during storage, but the beta-
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carotene encapsulated in SLN treatment showed much slower degradation than its encapsulation
with soybean oil. By the end of storage, about 94.8% loss of the beta-carotene concentration and
97.4% loss of net antioxidant potential were observed for the latter system. In contrast, the
concentration and net antioxidant potential of beta-carotene encapsulated in SLNs only
decreased by 47.3% and 66.7%, respectively. The concentration change of encapsulated betacarotene (Figure 2.9B) followed the first order kinetics, as reported previously for beta-carotene
in safflower seed oil 50. The results indicate the effectiveness of SLNs in reducing the
degradation of encapsulated bioactive compounds during storage.
To prove the reduced degradation in SLNs is due to the lowered mobility in the solid
lipid phase, 0.0125 mM beta-carotene was dissolved in soybean oil or AMF and stored at 65 °C
and room temperature (21 °C) for 16 days, and the absorbance at 450 nm was measured to
monitor changes in beta-carotene content, with the corresponding lipids as a control. Betacarotene degraded much faster in melted AMF (79.0 %) than in soybean oil (28.9%) at 65 °C,
suggesting soybean oil having better antioxidant properties. At 21 °C, beta-carotene did not show
obvious degradation in both lipids. Since soybean oil has better antioxidant properties, it
suggests that the amorphous solid state of AMF reduces the mobility of molecules and free
radicals to reach similar stability as beta-carotene in soybean oil. The degradation tests in bulk
lipids further support the conclusion that the enhanced stability of beta-carotene in SLNs is due
to the amorphous solid state of AMF.
In summary, the present study demonstrated the feasibility to prepare transparent
dispersions of SLNs composed of AMF as the solid lipid dispersed phase and Tween 80 as a
nonionic surfactant by using the PIT method. Thermal treatment conditions, salinity, and
surfactant-to-oil ratio all played important roles in the effectiveness of transforming turbid
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emulsions into transparent ones after heating. An increase of salinity lowered the PIT, thus
favoring the formation of transparent SLN dispersions. A higher surfactant concentration enabled
the incorporation of a higher amount of AMF in transparent SLN dispersions. SLN dispersions
remained stable upon dilution and showed practically no changes in particle size and turbidity
during storage for 90 days at 21 °C. Beta-carotene was successfully encapsulated in SLNs using
the PIT method and had much better stability in SLNs than in soybean oil-based nanoemulsions.
Therefore, the simple PIT method and AMF can be used to form stable and transparent SLN
dispersions for incorporation of a variety of lipophilic bioactive compounds in functional
beverages.
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Figure 2.1. Absorbance at 600 nm (Abs600) of dispersions containing 1% w/w AMF and aqueous
phase with 15% w/w Tween 80 dissolved in 0-1.0 M NaCl solutions after heating at a
temperature between 80 and 95 C for 30 min and cooling to room temperature. Error bars are
standard deviations from duplicate samples.
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Figure 2.2A. The change of viscosity during cooling from 95 to 35 ℃ for an emulsion. The
phase inversion temperature (PIT) was determined from the local minimum, as depicted. As
shown in the inset, cooling results in the conversion of a W/O/W emulsion to an O/W emulsion.
The emulsion contained 1% w/w anhydrous milk fat (water fraction fw =0.99) and an aqueous
phase composed of 15% w/w Tween 80 dissolved in a 0.8 M NaCl solution.
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Figure 2.2B. Effects of NaCl concentration on the viscosity of emulsions during cooling from 95
to 35 ℃. Emulsions contained 1% w/w AMF and an aqueous phase with 15% w/w Tween 80
dissolved in 0-1.0 M NaCl solutions. Values of the phase inversion temperature (PIT), obtained
as described in Figure 2.2A, were listed in the legend.
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Figure 2.3. Appearance of emulsions before (top) and after (bottom) heating at 90 C for 30 min.
Emulsions before heating were prepared with 1.0-15.0% w/w AMF and an aqueous phase with
30% w/w Tween 80 dissolved in a 0.8 M NaCl solution. AMF concentration increased by 1%
w/w successively for samples ordered from left to right.
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Figure 2.4. Partial phase diagram showing conditions (×100%w/w for each constituent) of
forming microemulsions (red squares), transparent SLNs dispersions (green circles) and turbid or
phase-separated emulsions (blue triangles) at 25 C formed by the phase inversion temperature
method. Coarse emulsions were prepared by mixing 1-15% w/w AMF with an aqueous phase
with 10-40% w/w Tween 80 dissolved in a 0.8 M NaCl solution and were heated at 90 C for 30
min.
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Figure 2.5. Absorbance at 600 nm (Abs600) of emulsions after heating at 90 C for 30 min and
cooling to room temperature. Emulsions were prepared with 1.0-15.0% w/w AMF and an
aqueous phase with 10-40% w/w Tween 80 dissolved in a 0.8 M NaCl solution. Error bars are
standard deviations from duplicate samples.
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Figure 2.6. Volume-length mean diameter (d4,3) of emulsions after heating at 90 C for 30 min
and cooling to room temperature. Emulsions were prepared with 1.0-15.0% w/w AMF and an
aqueous phase with 10-40% w/w Tween 80 dissolved in a 0.8 M NaCl solution. Samples that
exhibited creaming within 10 min after thermal treatment are not plotted. Error bars are standard
deviations from duplicate samples.
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Figure 2.7. Atomic force microscopy topographic image with a dimension of 2 × 2 µm (A) and
height distribution of particles along the measurement line (B). Particle size distribution of SLNs
from light scattering is plotted in (C) for comparison. The SLNs were prepared by heating at 90
C for 30 min using an emulsion prepared with 10% w/w AMF in an aqueous phase with 30%
w/w Tween 80 dissolved in a 0.8 M NaCl solution.
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Figure 2.8. XRD patterns of pristine beta-carotene (blue), AMF (red) and beta-carotene-loaded
SLNs (black). SLNs were prepared by heating at 90 C for 30 min using an emulsion prepared
with 10% w/w AMF in an aqueous phase with 30% w/w Tween 80 dissolved in a 0.8 M NaCl
solution.
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Figure 2.10. Changes of (A) volume-length mean diameter (d4,3) and (B) absorbance at 600 nm
(Abs600) of SLNs dispersions, with and without dialysis, during 90-day storage at room
temperature (21 C). SLNs prepared by heating at 90 C for 30 min using an emulsion prepared
with 10% w/w AMF in an aqueous phase with 30% w/w Tween 80 dissolved in a 0.8 M NaCl
solution. Error bars are standard deviations from duplicate samples.
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Figure 2.11. Changes of antioxidant properties of beta-carotene-loaded SLNs dispersions during
storage at room temperature (21 C), in comparison to a control with beta-carotene encapsulated
in vegetable oil-based nanoemulsion. Error bars are standard deviations from duplicate samples.
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Conclusions
SLNs are nanoparticles that contain a solid lipid core and have potential applications in
the food industry. Many approaches used to prepare conventional nanoemulsions can be used to
prepare SLNs, including high energy and low energy methods. High energy methods include hot
and cold HPH methods, high shear homogenization and ultrasonication methods, while solvent
evaporation is a low energy method. SLNs can also be prepared from self-assembled
microemulsions. The degradation of bioactives during sample preparation and possible organic
solvent residues are concerns for food applications.

The degradation and release of bioactives incorporated in SLNs mainly depend on the
exact structure of SLNs with regard to the spatial distributions of the bioactives and carrier
lipids. Burst release and faster degradation of bioactives are commonly observed when the
encapsulated compound is mostly present in the outer shell. The prolonged release and improved
stability of bioactives correspond to situations where bioactives are rich in the lipid core or
distributed evenly in the SLNs.

In this thesis, a phase inversion temperature method was used to prepared milk fat-based
SLNs. This method only required a thermal treatment to cause phase inversion of the system.
AMF is a mixture of more than 40 kinds of lipids with different chain lengths. The impurity of
lipids can benefit the formation of less perfect crystals, or even amorphous solids. This kind of
structure would increase the loading of bioactives in SLNs and thus avoid the burst release. A
mixture of different lipids can also increase physical stability of SLNs by preventing crystal
transformation in the later storage. A food grade nonionic surfactant, Tween 80, was used to
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prepare the system. NaCl was added to the system to lower the PIT and therefore facilitate phase
inversion.

Thermal treatment conditions, salinity, and surfactant-to-oil ratio all played important
roles in the effectiveness of transforming turbid emulsions into transparent ones after heating. An
increase of salinity lowered the PIT, thus favoring the formation of transparent SLN dispersions.
A higher surfactant concentration enabled the incorporation of a higher amount of AMF in
transparent SLN dispersions. The prepared transparent SLNs have relatively small particle
diameters (23 nm). SLN dispersions remained stable upon dilution and had consistent particle
size and turbidity during 90 day storage at room temperature.

Beta-carotene was used as a model lipophilic bioactive compound. Compared with
soybean oil-based nanoemulsions, beta-carotene showed a much longer storage stability in terms
of residual concentrations and antioxidant properties. Therefore, the simple PIT method and
AMF can be used to form stable and transparent SLN dispersions for incorporation of a variety
of lipophilic bioactive compounds in functional beverages. A further study may be needed to
understand the lipid core structure in SLNs, as well as their stability in model food systems.
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